Compare Amgen, Inc. (AMGN) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Endeavour Silver Corp — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Endeavour Silver Corp trades at $7.85 (market cap $2.39B). The key difference: Amgen, Inc. is far larger — about 82.1× Endeavour Silver Corp's market cap, and Amgen, Inc. pays a 2.77% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| AMGN | EXK | |
|---|---|---|
Market Cap | $196.12B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $14.12 |
52-Week Low | $271.18 | $4.96 |
Enterprise Value | $241.41B | $2.40B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Endeavour Silver (EXK) trades at $8.08, down 1.94% with bearish technical signals despite strong Q2 2026 production results. The company shows improving fundamentals with Q1 2026 earnings beating estimates at $0.21 per share versus $0.10 expected, while revenue trends project growth from $468M in 2025 to $614M in 2026. Analyst sentiment remains overwhelmingly positive with 11 buy ratings out of 14 total recommendations.
EXK presents a recovery opportunity as silver prices strengthen and production expands, though negative net margins and high valuation ratios pose near-term risks. The expiration of silver collars in June 2026 could unlock significant cash flow, providing catalysts for upside potential despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
